文献速递炎症性肠病

STAR SIGN研究:评估COVID-19疫苗对炎症性肠病患者中SARS-CoV-2变异株BQ.1.1和XBB.1.5的效力

STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2023-08-12

这项前瞻性多中心病例对照研究纳入98例生物制剂治疗的炎症性肠病患者和48例健康对照,评估第三剂疫苗接种后对奥密克戎亚分支BQ.1.1和XBB.1.5的替代中和能力。结果显示,接受抗TNF生物制剂治疗的患者对所有测试亚分支的替代中和能力均降低,且时间推移后下降,突破性感染可提高中和能力。

要点

  • 抗TNF生物制剂治疗患者对BQ.1.1和XBB.1.5的替代中和能力低于非抗TNF治疗患者和健康对照。
  • 抗TNF治疗与低野生型替代中和相关(OR 0.29,95%CI 0.19-0.46)。
  • mRNA-1273疫苗接种与高野生型替代中和相关(OR 1.86,95%CI 1.12-3.08)。

核心结论

  • 接受抗TNF生物制剂治疗的炎症性肠病患者对新奥密克戎亚分支BQ.1.1和XBB.1.5的中和能力受损,可能受益于未来变异株适配疫苗的优先接种。

研究设计与样本

  • 前瞻性多中心病例对照研究,纳入98例生物制剂治疗的炎症性肠病患者和48例健康对照。
  • 在第三剂疫苗接种后两个时间点(2-16周和22-40周)测量抗刺突IgG浓度和替代中和能力。

主要发现

  • 第一次访视时,抗TNF生物制剂治疗患者对所有测试亚分支的替代中和能力低于非抗TNF治疗患者和健康对照(各p≤0.001)。
  • 第一次访视时,抗TNF生物制剂治疗患者中对奥密克戎亚分支替代中和不足的比例高于非抗TNF治疗患者和健康对照(各p≤0.015)。
  • 所有测试亚分支的替代中和能力随时间下降,但突破性感染可提高中和能力。
  • 抗刺突IgG浓度与替代中和能力相关。

关键数值与推荐

  • 抗TNF治疗与低野生型替代中和相关(OR 0.29,95%CI 0.19-0.46)。
  • 疫苗接种后时间与低野生型替代中和相关(OR 0.85,95%CI 0.72-1.00)。
  • mRNA-1273疫苗接种与高野生型替代中和相关(OR 1.86,95%CI 1.12-3.08)。

临床怎么用

  • 接受抗TNF生物制剂治疗的炎症性肠病患者可能受益于未来变异株适配疫苗的优先接种。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccine-elicited immune responses are impaired in patients with inflammatory bowel disease (IBD) treated with anti-TNF biologics. AIMS: To assess vaccination efficacy against the novel omicron sublineages BQ.1.1 and XBB.1.5 in immunosuppressed patients with IBD. METHODS: This prospective multicentre case-control study included 98 biologic-treated patients with IBD and 48 healthy controls. Anti-spike IgG concentrations and surrogate neutralisation against SARS-CoV-2 wild-type, BA.1, BA.5, BQ.1.1, and XBB.1.5 were measured at two different time points (2-16 weeks and 22-40 weeks) following third dose vaccination. Surrogate neutralisation was based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Primary outcome was surrogate neutralisation against tested SARS-CoV-2 sublineages. Secondary outcomes were proportions of participants with insufficient surrogate neutralisation, impact of breakthrough infection, and correlation of surrogate neutralisation with anti-spike IgG concentration. RESULTS: Surrogate neutralisation against all tested sublineages was reduced in patients with IBD who were treated with anti-TNF biologics compared to patients treated with non-anti-TNF biologics and healthy controls (each p ≤ 0.001) at visit 1. Anti-TNF therapy (odds ratio 0.29 [95% CI 0.19-0.46]) and time since vaccination (0.85 [0.72-1.00]) were associated with low, and mRNA-1273 vaccination (1.86 [1.12-3.08]) with high wild-type surrogate neutralisation in a β-regression model. Accordingly, higher proportions of patients treated with anti-TNF biologics had insufficient surrogate neutralisation against omicron sublineages at visit 1 compared to patients treated with non-anti-TNF biologics and healthy controls (each p ≤ 0.015). Surrogate neutralisation against all tested sublineages decreased over time but was increased by breakthrough infection. Anti-spike IgG concentrations correlated with surrogate neutralisation. CONCLUSIONS: Patients with IBD who are treated with anti-TNF biologics show impaired neutralisation against novel omicron sublineages BQ.1.1 and XBB.1.5 and may benefit from prioritisation for future variant-adapted vaccines.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Woelfel S, Dütschler J, König M, et al. STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2023. PMID: 37571863. doi:10.1111/apt.17661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。